Cardiovascular involvement in COVID-19 : not to be missed
In December 2019, a striking appearance of new cases of viral pneumonia in Wuhan led to the detection of a novel coronavirus (SARS-CoV2). By analyzing patients with severe manifestations, it became apparent that 20 to 35% of patients who died had preexisting cardiovascular disease. This finding warrants the important need to discuss the influence of SARS-CoV2 infection on the cardiovascular system and hemodynamics in the context of clinical management, particularly during mechanical ventilation. The SARS-CoV2 enters human cells through the spike protein binding to angiotensin-converting enzyme 2 (ACE2), which is important to cardiovascular modulation and endothelial signaling. As ACE2 is highly expressed in lung tissue, patients have been progressing to acute respiratory injury at an alarming frequency during the Coronavirus Disease (COVID-19) pandemic. Moreover, COVID-19 leads to high D-dimer levels and prothrombin time, which indicates a substantial coagulation disorder. It seems that an overwhelming inflammatory and thrombogenic condition is responsible for a mismatching of ventilation and perfusion, with a somewhat near-normal static lung compliance, which describes two types of pulmonary conditions. As such, positive pressure during invasive mechanical ventilation (IMV) must be applied with caution. The authors of this review appeal to the necessity of paying closer attention to assess microhemodynamic repercussion, by monitoring central venous oxygen saturation during strategies of IMV. It is well known that a severe respiratory infection and a scattered inflammatory process can cause non-ischemic myocardial injury, including progression to myocarditis. Early strategies that guide clinical decisions can be lifesaving and prevent extended myocardial damage. Moreover, cardiopulmonary failure refractory to standard treatment may necessitate the use of extreme therapeutic strategies, such as extracorporeal membrane oxygenation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Brazilian journal of cardiovascular surgery - 35(2020), 4 vom: 01. Aug., Seite 530-538 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rocco, Isadora S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin Converting Enzyme 2 |
|---|
| Anmerkungen: |
Date Completed 03.09.2020 Date Revised 18.12.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.21470/1678-9741-2020-0224 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31438071X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31438071X | ||
| 003 | DE-627 | ||
| 005 | 20231225152614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21470/1678-9741-2020-0224 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM31438071X | ||
| 035 | |a (NLM)32864934 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rocco, Isadora S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular involvement in COVID-19 |b not to be missed |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.09.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In December 2019, a striking appearance of new cases of viral pneumonia in Wuhan led to the detection of a novel coronavirus (SARS-CoV2). By analyzing patients with severe manifestations, it became apparent that 20 to 35% of patients who died had preexisting cardiovascular disease. This finding warrants the important need to discuss the influence of SARS-CoV2 infection on the cardiovascular system and hemodynamics in the context of clinical management, particularly during mechanical ventilation. The SARS-CoV2 enters human cells through the spike protein binding to angiotensin-converting enzyme 2 (ACE2), which is important to cardiovascular modulation and endothelial signaling. As ACE2 is highly expressed in lung tissue, patients have been progressing to acute respiratory injury at an alarming frequency during the Coronavirus Disease (COVID-19) pandemic. Moreover, COVID-19 leads to high D-dimer levels and prothrombin time, which indicates a substantial coagulation disorder. It seems that an overwhelming inflammatory and thrombogenic condition is responsible for a mismatching of ventilation and perfusion, with a somewhat near-normal static lung compliance, which describes two types of pulmonary conditions. As such, positive pressure during invasive mechanical ventilation (IMV) must be applied with caution. The authors of this review appeal to the necessity of paying closer attention to assess microhemodynamic repercussion, by monitoring central venous oxygen saturation during strategies of IMV. It is well known that a severe respiratory infection and a scattered inflammatory process can cause non-ischemic myocardial injury, including progression to myocarditis. Early strategies that guide clinical decisions can be lifesaving and prevent extended myocardial damage. Moreover, cardiopulmonary failure refractory to standard treatment may necessitate the use of extreme therapeutic strategies, such as extracorporeal membrane oxygenation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Angiotensin Converting Enzyme 2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cardiovascular Diseases | |
| 650 | 4 | |a Extracorporeal Membrane Oxygenation | |
| 650 | 4 | |a Mechanical Ventilation | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Pneumonia, Viral | |
| 650 | 4 | |a SARS-CoV2 | |
| 700 | 1 | |a Gomes, Walter J |e verfasserin |4 aut | |
| 700 | 1 | |a Viceconte, Marcela |e verfasserin |4 aut | |
| 700 | 1 | |a Bolzan, Douglas W |e verfasserin |4 aut | |
| 700 | 1 | |a Moreira, Rita Simone L |e verfasserin |4 aut | |
| 700 | 1 | |a Arena, Ross |e verfasserin |4 aut | |
| 700 | 1 | |a Guizilini, Solange |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brazilian journal of cardiovascular surgery |d 2015 |g 35(2020), 4 vom: 01. Aug., Seite 530-538 |w (DE-627)NLM256179859 |x 1678-9741 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2020 |g number:4 |g day:01 |g month:08 |g pages:530-538 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21470/1678-9741-2020-0224 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2020 |e 4 |b 01 |c 08 |h 530-538 | ||